Dasatinib Hydrate

达沙替尼

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameDasatinib Hydrate
Drug Alias Name达莎菲尼Dasatinibum达莎非尼dasatanib达莎替尼 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase FYN inhibitorsTyrosine-protein kinase SRC inhibitorsBcr-Abl tyrosine kinase inhibitors +[8] 
TargetsTyrosine-protein kinase FYNEphrin type-A receptor 2Stem cell growth factor receptor +[8] 
Therapy Area/IndicationsBone metastasesCoronavirus Disease 2019 (COVID-19)Skin Melanoma +[106] 
Global Approved IndicationsLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Approved Indications in ChinaLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Original Approved Country/TerritoryUnited States
Original Approved Date2006/06/28
Country/TerritoryCzechiaBelgiumCanada +[48] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co LtdHanda Therapeutics Llc +[17] 
Inactive CompaniesDana-Farber Cancer InstituteHamad Medical CorporationUniversity of California Irvine +[22] 
Active IndicationsBreast NeoplasmsMesotheliomaGlioma +[10] 
Inactive IndicationsBone metastasesCoronavirus Disease 2019 (COVID-19)Skin Melanoma +[96] 

Other Information

ATC CodeL01EA02
Related LinksWikipediaDrugBankKEGG